secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001628280-25-024095
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen Q1 2025 net loss $0.05/sh; cash $38.1M; OCU400 Phase 3 on track for mid-2026 BLA/MAA
--------------------------------------------------------------------------------

- Cash & restricted cash $38.1M as of Mar 31, 2025, down from $58.8M at Dec 31, 2024; runway into Q1 2026.
- Operating expenses $16.0M (R&D $9.5M, G&A $6.5M) vs $13.2M in Q1 2024; net loss per share unchanged at $0.05.
- OCU400 Phase 3 liMeliGhT RP trial recruiting; BLA/MAA filings targeted by mid-2026; ATMP classification from EMA.
- OCU410ST Phase 2/3 pivotal trial for Stargardt disease to start mid-2025; BLA filing target 2027.
- OCU410 for GA: Phase 2 dosing complete; 12-month data shows 4-line VA gain and 41% slower lesion growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828025024095/0001628280-25-024095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828025024095/ocgn-20250509.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-024095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer